As Januvia, Byetta Lawsuits are Consolidated to California Federal Court, Morgan & Morgan Continues to Review Pancreatic Cancer Claims

Share Article

Morgan & Morgan continues to review claims on behalf of Januvia, Byetta, Janumet and Victoza users who were diagnosed with pancreatic cancer as litigation involving the diabetes drugs continues to move forward. On Aug. 26, a panel of federal judges consolidated lawsuits involving the four popular diabetes drugs to a single court.

Our firm has spoken with dozens of clients who claim that these drugs cause life-threatening pancreatic cancer. I’m pleased to see that the suits have been consolidated to help diabetes patients and their loved ones see their cases resolved efficiently.

The attorneys at Morgan & Morgan continue to review pancreatic cancer claims on behalf of Januvia, Byetta, Janumet and Victoza users as litigation involving the diabetes drugs continues to move forward. On Aug. 26, a panel of federal judges consolidated more than 50 lawsuits alleging that the drugs cause pancreatic cancer to the U.S. District Court for the Southern District of California.*

“Consolidation of these suits is a significant development in the pending legal action against makers of diabetes drugs,” said Michael Goetz, head of Morgan & Morgan’s mass tort section. “Our firm has spoken with dozens of clients who claim that these drugs cause life-threatening pancreatic cancer. I’m pleased to see that the suits have been consolidated to help diabetes patients and their loved ones see their cases resolved efficiently.”

While the panel on multidistrict litigation (MDL) noted that it is “typically hesitant” to consolidate cases against multiple defendants that sold similar products, it found that the plaintiffs’ allegations were “highly similar,” according to the transfer order.** The plaintiffs in the suits allege that use of one or more of four popular diabetes drugs – Januvia, Byetta, Janumet or Victoza – caused them or a loved one to develop pancreatic cancer, the transfer order notes. The suits were prompted by research that revealed a possible link between a class of diabetes drugs known as incretin mimetics and pre-cancerous cell changes in the pancreas, a potential risk outlined in a March 2013 FDA drug safety communication. ***

Centralization of the suits will facilitate the discovery process, preserve the resources of all parties involved in the litigation, and help ensure consistent rulings, according to the transfer order. Most of the suits are now pending before the Honorable Judge Anthony J. Battaglia.

For more information on the pending lawsuits, please visit http://www.forthepeople.com/class-action-lawyers. Morgan & Morgan is currently offering free online consultations to Januvia, Byetta, Janumet and Victoza users who were diagnosed with pancreatic cancer, as well as loved ones acting on their behalf. These consultations are being offered at no cost and with no obligation.

About Morgan & Morgan

Morgan & Morgan is one of the largest exclusively plaintiffs’ law firms in the country with 15 offices throughout Florida, Georgia, Mississippi, Tennessee, and New York. The firm handles cases nationally involving personal injury, medical malpractice, consumer class action, and securities fraud, as well as complex litigation against drug and medical device manufacturers. Visit Morgan & Morgan online at http://www.forthepeople.com/ for a free case evaluation and information about your legal rights.

  • Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452

** jpml.uscourts.gov/sites/jpml/files/MDL-2452-Initial_Transfer-07-13.pdf
***http://www.fda.gov/drugs/drugsafety/ucm343187.htm

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Goetz
Visit website